Anti-gd2 antibody for treatment of neuroblastoma

Abstract

The invention relates to anti-ganglioside GD2 antibodies that comprise an antibody variable domain and antibody constant domains, wherein the variable domain comprises a heavy and light chain variableregion comprising respectively at least the CDR3 of the heavy chain variable region of antibody ch14.18 and at least the CDR3 of the light chain variable region of antibody ch14.18; and an IgA hingeand CH2 domain and to methods of treatment of subjects with a GD2 positive tumor, preferably neuroblastoma with these antibodies.

Description

technical field [0001] The present invention relates to the field of antibodies. Specifically, it relates to antibodies that bind the ganglioside GD2. It also relates to the use of the GD2 antibody in medical and detection methods. The invention also relates to cells, nucleic acid molecules and methods for producing antibodies. Background technique [0002] Neuroblastoma, the most common extracranial solid tumor in childhood, accounts for approximately 12% of all childhood cancer deaths. Most patients are diagnosed with high-risk neuroblastoma with a 50% mortality rate. Neuroblastoma therapy includes intensive combination therapy with severe toxicities. High-risk neuroblastoma therapy includes intensive combination therapy with severe short- and long-term toxicities. Relapse rates are high, and further treatment options are limited. Residual disease is treated with intensive chemotherapy, radiotherapy, high-dose chemotherapy followed by autologous hematopoietic stem ce...

AI Technical Summary

Problems solved by technology

Many of these toxicities are dose-dependent and rarely noticed at low doses

Images